Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin glargine/lixisenatide - Sanofi

Drug Profile

Insulin glargine/lixisenatide - Sanofi

Alternative Names: AVE0010/Lantus®; HOE901/AVE0010; iGlarLixi; Insulin glargine/lixisenatide; Lantus®/lixisenatide single combination product; Lantus®/Lyxumia®; LixiLan; Lixisenatide + Lantus®; Lixisenatide/Lantus®; Lyxumia®/Lantus®; Soliqua; Soliqua®100/33; Suliqua

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis; Zealand Pharma
  • Developer Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 25 Nov 2019 Sanofi completes the phase III LixiLan-India trial in Type-2 diabetes mellitus (New delivery system) in India (SC) (NCT03529123)
  • 09 Oct 2019 Launched for Type 2 diabetes mellitus (Adjunctive treatment, New delivery system) in Switzerland (SC)
  • 16 Sep 2019 Efficacy and safety data from a phase III LixiLan-G trial in Type 2 diabetes mellitus presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD-2019)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top